Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD2 | Q8N5K1 | 12/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | GUSB | P08236 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838904 | 1.00 | CISD2 (0.66) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838885 | 0.94 | CISD2 (0.63) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838884 | 0.92 | CISD2 (0.65) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838915 | 0.91 | CISD2 (0.60) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838917 | 0.88 | CISD2 (0.84) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838905 | 0.87 | ADORA1 (0.67) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838902 | 0.85 | CISD2 (0.62) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838878 | 0.85 | CISD2 (0.58) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL20838911 | 0.81 | NPC1 (0.53) | CISD2ADORA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL25106705 | 0.80 | CISD2 (1.00) | CISD2ADORA1RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | HAVCR2, ZC3HAV1, HCCS | CISD2 3262/4885ADORA1 4438/4885RAB9A 1487/4885 |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | HAVCR2, ZC3HAV1, HCCS | CISD2 3262/4885ADORA1 4438/4885RAB9A 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.